Neoplasms, Glandular and Epithelial
30
3
7
9
Key Insights
Highlights
Success Rate
64% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
16.7%
5 terminated out of 30 trials
64.3%
-22.3% vs benchmark
13%
4 trials in Phase 3/4
56%
5 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 9 completed trials
Clinical Trials (30)
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Vorasidenib Expanded Access Program
Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma
Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Intended Use Study of the BD SurePath Plus™ Pap
Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
HR Versus RFA for HCC in Patients With PHT
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer